DK0846173T3 - Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma - Google Patents

Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma

Info

Publication number
DK0846173T3
DK0846173T3 DK96929657T DK96929657T DK0846173T3 DK 0846173 T3 DK0846173 T3 DK 0846173T3 DK 96929657 T DK96929657 T DK 96929657T DK 96929657 T DK96929657 T DK 96929657T DK 0846173 T3 DK0846173 T3 DK 0846173T3
Authority
DK
Denmark
Prior art keywords
interleukin
antibody
asthma
drug
produce
Prior art date
Application number
DK96929657T
Other languages
English (en)
Inventor
Roy Clifford Levitt
Nicolas Nicolaides
W Lee Maloy
Prasad U Kari
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of DK0846173T3 publication Critical patent/DK0846173T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5425IL-9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96929657T 1995-08-24 1996-08-23 Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma DK0846173T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2380096P 1996-08-06 1996-08-06

Publications (1)

Publication Number Publication Date
DK0846173T3 true DK0846173T3 (da) 2006-01-16

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96929657T DK0846173T3 (da) 1995-08-24 1996-08-23 Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
DK05009688.2T DK1632248T3 (da) 1995-08-24 1996-08-23 Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05009688.2T DK1632248T3 (da) 1995-08-24 1996-08-23 Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed

Country Status (10)

Country Link
EP (3) EP2241329A3 (da)
JP (3) JP3948495B2 (da)
AT (2) ATE484294T1 (da)
AU (1) AU6895696A (da)
CA (2) CA2666298A1 (da)
DE (2) DE69635305T2 (da)
DK (2) DK0846173T3 (da)
ES (2) ES2249786T3 (da)
PT (1) PT1632248E (da)
WO (1) WO1997008321A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
EP1471144B1 (en) * 1996-12-02 2010-06-23 Genaera Corporation Biological variability of asthma associated factor AAF2 (IL-9 receptor) useful in treating and diagnosing atopic allergies including asthma and related disorders
PT1471144E (pt) * 1996-12-02 2010-08-17 Genaera Corp Variabilidade biológica de factor associado a asma aaf2 (receptor de il-9) útil no tratamento e diagnóstico de alergias atópicas incluindo asma e distúrbios relacionados
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
CA2302782A1 (en) * 1997-09-19 1999-03-25 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU760274B2 (en) * 1997-09-19 2003-05-08 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2000066708A2 (en) * 1999-05-01 2000-11-09 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US20040219149A1 (en) 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
DE60236643D1 (de) * 2001-02-22 2010-07-22 Univ New York State Res Found Opiatrezeptoren
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
EP2364998A1 (en) 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Antibodies against HMGB1 and fragments thereof
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
AU2237395A (en) 1994-03-30 1995-10-23 University Of Maryland At Baltimore Human interleukin variants generated by alternative splicing

Also Published As

Publication number Publication date
JP2007169287A (ja) 2007-07-05
EP2241329A2 (en) 2010-10-20
EP1632248B8 (en) 2010-12-29
AU6895696A (en) 1997-03-19
WO1997008321A1 (en) 1997-03-06
JP3948495B2 (ja) 2007-07-25
CA2666298A1 (en) 1997-03-06
DK1632248T3 (da) 2011-01-24
ES2354360T3 (es) 2011-03-14
JP4813380B2 (ja) 2011-11-09
EP2241329A3 (en) 2011-03-09
EP1632248B1 (en) 2010-10-13
EP0846173B1 (en) 2005-10-19
CA2230240C (en) 2009-08-18
EP1632248A1 (en) 2006-03-08
DE69635305D1 (de) 2006-03-02
CA2230240A1 (en) 1997-03-06
DE69635305T2 (de) 2006-07-06
ATE484294T1 (de) 2010-10-15
JPH11514851A (ja) 1999-12-21
JP2011152135A (ja) 2011-08-11
DE69638281D1 (de) 2010-11-25
ES2249786T3 (es) 2006-04-01
PT1632248E (pt) 2010-12-28
ATE307203T1 (de) 2005-11-15
EP0846173A1 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
DK0846173T3 (da) Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DK1136093T3 (da) Apparat til kontrolleret inhalation af terapeutiske aerosoler
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
PT1041990E (pt) Composicao para o tratamento de doencas respiratorias e doencas de pele, compreendendo pelo menos um antagonista de leucotrieno e pelo menos um anti-histaminico
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
DK0751129T6 (da) Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
DK0998287T3 (da) Anvendelse af levobupivacain
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
EP1440689A3 (en) Treatment of neurotic disorders
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
NO990450L (no) Behandling av sinnslidelser
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
MA26592A1 (fr) Procede et medicament utilisant des composes cycliques, pour le traitement de la bronchopneumopathie chronique obstructive
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
DE69734461D1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.